ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $77.71 Average PT from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $77.71.

ANIP has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. Truist Financial raised their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Raymond James boosted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Finally, Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th.

Insider Transactions at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. The trade was a 8.29 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,231 shares of company stock valued at $2,434,286. Company insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Texas Permanent School Fund Corp raised its position in shares of ANI Pharmaceuticals by 1.3% in the 2nd quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock worth $852,000 after purchasing an additional 178 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of ANI Pharmaceuticals by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after buying an additional 200 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of ANI Pharmaceuticals by 4.7% during the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after buying an additional 211 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after acquiring an additional 299 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its position in ANI Pharmaceuticals by 1.7% in the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after acquiring an additional 394 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Up 2.0 %

Shares of ANIP stock opened at $55.28 on Friday. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $70.81. The business’s fifty day moving average is $57.16 and its 200 day moving average is $59.42. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market capitalization of $1.16 billion, a PE ratio of -100.51 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same quarter last year, the company posted $1.05 EPS. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities research analysts anticipate that ANI Pharmaceuticals will post 3.87 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.